Using antimicrobial adjuvant therapy in cancer treatment: A review

Infectious Agents and Cancer

Volumn 7, Issue 1, 2012, Pages

  Alibek, Kenneth ^a,b   Bekmurzayeva, Aliya ^a   Mussabekova, Assel ^a   Sultankulov, Bolat ^a  

^a NAZARBAYEV UNIVERSITY   (Kazakhstan)

^b Republican Scientific Center for Emergency Care   (Kazakhstan)

Author keywords

Antibiotic; Antiviral; Apoptosis; Bacteria; Cancer; Chemotherapy; Neutropenia; Virus

Indexed keywords

ACICLOVIR; ALPHA INTERFERON; AMOXICILLIN; ANTIVIRUS AGENT; CEFAZOLIN; CELECOXIB; CIDOFOVIR; CIPROFLOXACIN; CLARITHROMYCIN; CLIOQUINOL; COLONY STIMULATING FACTOR; COTRIMOXAZOLE; DAUNORUBICIN; DOXORUBICIN; ETOPOSIDE; FOSCARNET; GANCICLOVIR; LANSOPRAZOLE; LEVOFLOXACIN; MOXIFLOXACIN; NITROFURANTOIN; OMEPRAZOLE; POSACONAZOLE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIBAVIRIN; RITUXIMAB; SUCRALFATE; UNINDEXED DRUG; VALPROIC ACID; ZIDOVUDINE;

ADJUVANT THERAPY; APOPTOSIS; BACTEREMIA; BACTERIUM; BLADDER CARCINOMA; BRAIN TUMOR; CANCER CHEMOTHERAPY; CANCER THERAPY; DRUG EFFICACY; DRUG USE; GLIOBLASTOMA; GRAFT VERSUS HOST REACTION; HELICOBACTER INFECTION; HUMAN; HUMAN HERPESVIRUS 8; KAPOSI SARCOMA; LIVER CELL CARCINOMA; METASTASIS; NASOPHARYNX CARCINOMA; NEOPLASM; NEUTROPENIA; NONHUMAN; PRIORITY JOURNAL; PROPHYLAXIS; REVIEW; T CELL LEUKEMIA; T CELL LYMPHOMA;

EID: 84869186091     PISSN: None     EISSN: 17509378     Source Type: Journal    
DOI: 10.1186/1750-9378-7-33     Document Type: Review

References (84)

1. Comprehensive cancer information-national cancer institute 2012 http://www.cancer.gov/
2. Why do viruses cause cancer? Highlights of the first century of human tumour virology. Moore PS, Chang Y, Nat Rev Cancer 2010 10 12 878 21102637
3. Tumor viruses and cancer biology modulating signaling pathways for therapeutic intervention. Saha A, Kaul R, Murakami M, Robertson ES, Cancer Biol Ther 2010 10 10 1 18 21361067
4. How bacteria could cause cancer: One step at a time. Lax AJ, Thomas W, Trends Microbiol 2002 10 6 http://tim.trends.com
5. Does antiviral therapy prevent hepatocellular carcinoma? Kwon H, Lok AS, Antivir Ther 2011 16 6 787 795 10.3851/IMP1895 21900710
6. Virological suppression does not prevent the development of hepatocellular carcinoma in hbeag-negative chronic hepatitis b patients with cirrhosis receiving oral antiviral(s) starting with lamivudine monotherapy: Results of the nationwide hepnet. Greece cohort study. Papatheodoridis GV, Manolakopoulos S, Touloumi G, Vourli G, Raptopoulou-Gigi M, Vafiadis-Zoumbouli I, Vasiliadis T, Mimidis K, Gogos C, Ketikoglou I, Manesis EK, Gut 2011 10.1136/gut.2010.221846
7. Detection of human cytomegalovirus in medulloblastomas reveals a potential therapeutic target. Baryawno N, Rahbar A, Wolmer-Solberg N, Taher C, Odeberg J, Darabi A, Khan Z, Sveinbjornsson B, Fuskevag OM, Segerstrom L, Nordenskjold M, J Clin Investig 2011 121 10 4043 4055 10.1172/JCI57147 21946257
8. Acyclovir inhibition of ido to decrease tregs as a glioblastoma treatment adjunct. Soderlund J, Erhardt S, Kast RE, J Neuroinflammation 2010 7
9. Generation of polyclonal cmv-specific t cells for the adoptive immunotherapy of glioblastoma. Ghazi A, Ashoori A, Hanley PJ, Brawley VS, Shaffer DR, Kew Y, Powell SZ, Grossman R, Grada Z, Scheurer ME, Hegde M, J Immunother 2012 35 2 159 168 10.1097/CJI.0b013e318247642f 22306904
10. Pilot study of oral valganciclovir therapy in patients with classic kaposi sarcoma. Krown SE, Dittmer DP, Cesarman E, J Infect Dis 2011 203 8 1082 10.1093/infdis/jiq177 21450998
11. Update on kaposi's sarcoma and other hhv8 associated diseases. Part 1: Epidemiology, environmental predispositions, clinical manifestations, and therapy. Hengge UR, Ruzicka T, Tyring SK, Stuschke M, Roggendorf M, Schwartz RA, Seeber S, Lancet Infect Dis 2002 2 5 281 292 10.1016/S1473-3099(02)00263-3 12062994 (Pubitemid 34464739)
12. Effect of antiviral drugs used to treat cytomegalovirus end-organ disease on subsequent course of previously diagnosed kaposi's sarcoma in patients with aids. Robles R, Lugo D, Gee L, Jacobson MA, J Acquir Immune Defic Syndr Hum Retrovirol 1999 20 1 34 38 10.1097/00042560-199901010-00005 9928727 (Pubitemid 29045467)
13. Remission of hhv-8 and hiv-associated multicentric castleman disease with ganciclovir treatment. Corey Casper WGN, Meei-Li H, Lawrence C, Anna W, Blood 2004 103 1632 1634 10.1182/blood-2003-05-1721 14615380 (Pubitemid 38268952)
14. Iarc monographs- classifications 2012 http://monographs.iarc.fr/ENG/ Classification/
15. Treatment of locally recurrent epstein-barr virus-associated nasopharyngeal carcinoma using the anti-viral agent cidofovir. Yoshizaki T, Wakisaka N, Kondo S, Murono S, Shimizu Y, Nakashima M, Tsuji A, Furukawa M, J Med Virol 2008 80 5 879 882 10.1002/jmv.21165 18360900 (Pubitemid 351500036)
16. Antiviral approaches for cancers related to epstein-barr virus and human papillomavirus. Abdulkarim B, Bourhis J, Lancet Oncol 2001 2 10 622 630 10.1016/S1470-2045(01)00520-4 11902553 (Pubitemid 32998542)
17. Azidothymidine and interferon-a induce apoptosis in herpesvirus associated lymphomas. Lee R, Cai J-P, Deyev V, Gill P, Cabral L, Wood C, Agarwal R, Xia W, Boise L, Podack E, Harrington W, Cancer Res 1999 59 5514 5520 10554028 (Pubitemid 29526467)
18. Brief report-treatment of adult t-cell leukemia-lymphoma with zidovudine and interferon-alfa. Hermine O, Bouscary D, Gessain A, Turlure P, Leblond V, Franck N, Buzynveil A, Rio B, Macintyre E, Dreyfus F, Bazarbachi A, N Engl J Med 1995 332 26
19. Treatment of adult t cell leukemia/lymphoma: Current strategy and future perspectives. Bazarbachi A, Hermine O, AIDS Res Hum Retroviruses 2001 17 79 92 (Pubitemid 32772825)
20. Anti-cd20 monoclonal antibody (rituximab) and cidofovir as successful treatment of an ebv-associated lymphoma with cns involvement. Hanel M, Fiedler F, Thorns C, Onkologie 2001 24 5
21. Outcome of combination antiviral therapy in chronic hepatitis c virus infection during therapy of acute lymphoblastic leukemia. Ayyub M, El-Moursy SA, Al-Abbas F, Saudi J Gastroenterol 2011 17 4 283 286 10.4103/1319-3767.82586 21727738
22. Antibiotic use and risk of gynecological cancer. Tamim HM, Musallam KM, Al Kadri HM, Boivin JF, Collet JP, Eur J Obstet Gynecol Reprod Biol 2011 159 2 388 393 10.1016/j.ejogrb.2011.06.018 21741150
23. Gastric malt lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Capelle LG, de Vries AC, Looman CWN, Casparie MK, Boot H, Meijer GA, Kuipers EJ, Eur J Cancer 2008 44 16 2470 2476 10.1016/j.ejca.2008.07. 005 18707866
24. Helicobacter pylori in the pathogenesis of gastric cancer and gastric lymphoma. Kim SS, Ruiz VE, Carroll JD, Moss SF, Cancer Lett 2011 305 2 228 238 10.1016/j.canlet.2010.07.014 20692762
25. Inhibition of helicobacter pylori growth and its cytotoxicity by 2-hydroxy 4-methoxy benzaldehyde of decalepis hamiltonii (wight & arn); a new functional attribute. Srikanta BM, Nayaka MAH, Dharmesh SM, Biochimie 2011 93 4 678 688 Epub 2010 10.1016/j.biochi.2010.12.009 21185348
26. Management and long-term follow-up of early stage h. Pylori-associated gastric malt-lymphoma in clinical practice: An italian, multicentre study. Andriani A, Miedico A, Tedeschi L, Patti C, Di Raimondo F, Leone M, Schinocca L, Romanelli A, Bonanno G, Linea C, Giustini M, Dig Liver Dis 2009 41 7 467 473 Epub 2008 Oct 21 10.1016/j.dld.2008.09.009 18945654
27. Molecular targeting of the oncogene eif4e in acute myeloid leukemia (aml): A proof-of-principle clinical trial with ribavirin. Assouline S, Culjkovic B, Cocolakis E, Rousseau C, Beslu N, Amri A, Caplan S, Leber B, Roy D-C, Miller WH Jr, Borden KLB, Blood 2009 114 2 10.1182/blood-2009-02-205153
28. Ribavirin suppresses eif4e-mediated oncogenic transformation by physical mimicry of the 7-methyl guanosine mrna cap. Kentsis A, Topisirovic I, Culjkovic B, Shao L, Borden KLB, Proc Natl Acad Sci U S A 2004 101 52 18105 18110 10.1073/pnas.0406927102 15601771 (Pubitemid 40054081)
29. Ribavirin treatment effects on breast cancers overexpressing eif4e, biomarker with prognostic specificity for luminal b-type breast cancer. Pettersson F, Yau C, Dobocan MC, Culjkovic-Kraljacic B, Retrouvay H, Puckett R, Flores LM, Krop IE, Rousseau C, Cocolakis E, Borden KLB, Clin Cancer Res 2011 17 9 2874 2884 Epub 2011 10.1158/1078-0432.CCR-10-2334 21415224
30. 17-allylamino-17-demethoxygeldanamycin (17-aag) is effective in down-regulating mutated, constitutively activated kit protein in human mast cells. Fumo G, Akin C, Metcalfe DD, Neckers L, Blood 2004 103 3 1078 1084 14551138 (Pubitemid 38129574)
31. Targeting hsp90 for cancer therapy. Mahalingam D, Swords R, Carew JS, Nawrocki ST, Bhalla K, Giles FJ, Br J Cancer 2009 100 10 1523 1529 10.1038/sj.bjc.6605066 19401686
32. Hsp90 is expressed and represents a therapeutic target in human oesophageal cancer using the inhibitor 17-allylamino-17-demethoxygeldanamycin. Wu X, Wanders A, Wardega P, Tinge B, Gedda L, Bergstrom S, Sooman L, Gullbo J, Bergqvist M, Hesselius P, Lennartsson J, Br J Cancer 2009 100 2 334 343 10.1038/sj.bjc.6604855 19142186
33. Anticancer activity of the antibiotic clioquinol. Ding WQ, Liu BL, Vaught JL, Yamauchi H, Lind SE, Cancer Res 2005 65 8 3389 3395 15833873 (Pubitemid 40524624)
34. In vivo modulation of angiogenic gene expression by acyclic nucleoside phosphonates pmedap and pmeg. Otova B, Hrdy J, Votruba I, Holy A, Anticancer Res 2009 29 1295 1302 19414378
35. Ribavirin as an anti-cancer therapy: Acute myeloid leukemia and beyond? Borden KLB, Culjkovic-Kraljacic B, Leuk Lymphoma 2010 51 10 1805 1815 10.3109/10428194.2010.496506 20629523
36. Tregs and rethinking cancer immunotherapy. Curiel TJ, J Clin Investig 2007 117 1167 1174 10.1172/JCI31202 17476346 (Pubitemid 46718401)
37. Telomeres, telomerase, and apoptosis. Mondello C, Scovassi AI, Biochemistry and Cell Biology-Biochimie Et Biologie Cellulaire 2004 82 4 498 507 10.1139/o04-048 15284903 (Pubitemid 39286965)
38. Radiosensitization effect of zidovudine on human malignant glioma cells. Zhou F-X, Liao Z-K, Dai J, Xiong J, Xie C-H, Luo Z-G, Liu S-Q, Zhou Y-F, Biochem Biophys Res Commun 2007 354 2 354 356 Epub 2007
39. Cisplatin combined with zidovudine enhances cytotoxicity and oxidative stress in human head and neck cancer cells via a thiol-dependent mechanism. Mattson DM, Ahmad IM, Dayal D, Parsons AD, Aykin-Burns N, Li L, Orcutt KP, Spitz DR, Dornfeld KJ, Simons AL, Free Radic Biol Med 2009 46 2 10.1016/j. freeradbiomed.2008.10.023
40. Advances in antiviral therapy. Wu JJ, Pang KR, Huang DB, Tyring SK, Dermatol Clin 2005 23 2 313 322 10.1016/j.det.2004.09.001 15837157
41. Synthesis and antitumor activity of new anthracycline analogues. Rho YS, Kim WJ, Yoo DJ, Kang RS, Chung SR, Bulletin of the Korean Chemical Society 2001 22 9 963
42. Anthracyclines: Molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Minotti G, Menna P, Salvatorelli E, Cairo G, Gianni L, Pharmacol Rev 2004 56 2 185 229 10.1124/pr.56.2.6 15169927 (Pubitemid 38720829)
43. Thiazole antibiotics target foxm1 and induce apoptosis in human cancer cells. Bhat UG, Halasi M, Gartel AL, PLoS One 2009 4 5 5592 10.1371/journal. pone.0005592 19440351
44. Thiazole antibiotics against breast cancer. Halasi M, Zhao H, Dahari H, Bhat UG, Gonzalez EB, Lyubimov AV, Tonetti DA, Gartel AL, Cell Cycle 2010 9 6 1214 1217 Epub 2010 10.4161/cc.9.6.10955 20410687
45. Moxifloxacin enhances antiproliferative and apoptotic effects of etoposide but inhibits its proinflammatory effects in thp-1 and jurkat cells. Fabian I, Reuveni D, Levitov A, Halperin D, Priel E, Shalit I, Br J Cancer 2006 95 8 1038 1046 10.1038/sj.bjc.6603355 17047652 (Pubitemid 44606830)
46. Ciprofloxacin induces apoptosis and inhibits proliferation of human colorectal carcinoma cells. Herold C, Ocker M, Ganslmayer M, Gerauer H, Hahn EG, Schuppan D, Br J Cancer 2002 86 3 443 448 10.1038/sj.bjc.6600079 11875713 (Pubitemid 34185131)
47. Suppression of human prostate cancer cell growth by ciprofloxacin is associated with cell cycle arrest and apoptosis. Aranha O, Grignon R, Fernandes N, McDonnell TJ, Wood DP, Sarkar FH, Int J Oncol 2003 22 4 787 794 12632069
48. Management of fever in neutropenic patients with different risks of complications. Klastersky J, Clin Infect Dis 2004 39 32 S37 10.1086/383050 15250018 (Pubitemid 38971473)
49. Safety and efficacy of activated transfected killer cells for neutropenic fungal infections. Lin L, Ibrahim AS, Baquir B, Fu Y, Applebaum D, Schwartz J, Wang A, Avanesian V, Spellberg B, J Infect Dis 2010 201 11 1708 1717 10.1086/652496 20397927
50. Infections in hematological malignancies. Walid K, Rami H, Salman N, Dis Mon 2012 58 4 239 249 10.1016/j.disamonth.2012.01.001 22449371
51. A comparison of outcome from febrile neutropenic episodes in children compared with adults: Results from four eortc studies. Hann I, Viscoli C, Paesmans M, Gaya H, Glauser M, Br J Haematol 1997 99 3 580 588 10.1046/j.1365-2141.1997.4453255.x 9401070 (Pubitemid 27519860)
52. Empiric therapy with carbenicillin and gentamicin for febrile patients with cancer and granulocytopenia. Schimpff S, Satterlee W, Young VM, Serpick A, N Engl J Med 1971 284 19 1061 1065 10.1056/NEJM197105132841904 4994878
53. Changing epidemiology of infections in patients with neutropenia and cancer: Emphasis on gram-positive and resistant bacteria. Zinner SH, Clin Infect Dis 1999 29 3 490 494 10.1086/598620 10530434 (Pubitemid 29439940)
54. Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the united states. Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB, Clin Infect Dis 2003 36 9 1103 10.1086/374339 12715303 (Pubitemid 36553108)
55. Recent changes in bacterial epidemiology and the emergence of fluoroquinolone-resistant escherichia coli among patients with haematological malignancies: Results of a prospective study on 823 patients at a single institution. Cattaneo C, Quaresmini G, Casari S, Capucci MA, Micheletti M, Borlenghi E, Signorini L, Re A, Carosi G, Rossi G, J Antimicrob Chemother 2008 61 3 721 728 10.1093/jac/dkm514 18218645 (Pubitemid 351321152)
56. Epidemiology of bacteremia and factors associated with multi-drug-resistant gram-negative bacteremia in hematopoietic stem cell transplant recipients. Oliveira AL, de Souza M, Carvalho-Dias VMH, Ruiz MA, Silla L, Tanaka PY, Simoes BP, Trabasso P, Seber A, Lotfi CJ, Zanichelli MA, Bone Marrow Transplant 2007 39 12 775 781 10.1038/sj.bmt.1705677 17438585 (Pubitemid 46901976)
57. Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Ramphal R, Clin Infect Dis 2004 39 25 S31 10.1086/383048 15250017 (Pubitemid 38971472)
58. Beta-lactam-resistant enterobacter bacteremia in febrile neutropenic patients receiving monotherapy. Johnson MP, Ramphal R, J Infect Dis 1990 162 4 981 983 10.1093/infdis/162.4.981 2205658 (Pubitemid 20336545)
59. A randomized trial of high-dose ciprofloxacin versus azlocillin and netilmicin in the empirical therapy of febrile neutropenic patients. Johnson PRE, Yin JAL, Tooth JA, J Antimicrob Chemother 1992 30 2 203 214 10.1093/jac/30.2.203 1399929
60. Emergence of MRSA in positive blood cultures from patients with febrile neutropenia-a cause for concern. Morris PG, Hassan T, McNamara M, Hassan A, Wiig R, Grogan L, Breathnach OS, Smyth E, Humphreys H, Support Care Cancer 2008 16 9 1085 1088 10.1007/s00520-007-0398-5 18274787
61. Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G, Biol Blood Marrow Transplant 2007 13 5 615 621 10.1016/j.bbmt.2007.01.078 17448922 (Pubitemid 46585935)
62. Chemotherapy-induced neutropenia in lung cancer patients: The role of antibiotic prophylaxis. Kouranos V, Dimopoulos G, Vassias A, Syrigos KN, Cancer Lett 2011 313(1 9 14
63. Antitumor activity of common antibiotics against superficial bladder cancer. Kamat AM, Lamm DL, Urology 2004 63 3 457 460 10.1016/j.urology.2003.10. 038 15028437
64. Quinolone antibiotics: A potential adjunct to intravesical chemotherapy for bladder cancer. Kamat AM, DeHaven JI, Lamm DL, Urology 1999 54 1 56 61 10.1016/S0090-4295(99)00064-3 10414727 (Pubitemid 29323333)
65. Primary antifungal prophylaxis in leukaemia patients. Maertens JA, Frere P, Lass-Florl C, Heinz W, Cornely OA, EJC Suppl 2007 5 2 43 48 (Pubitemid 47193191)
66. European guidelines for antifungal management in leukemia and hematopoietic stem cell transplant recipients: Summary of the ecil 3-2009 update. Maertens J, Marchetti O, Herbrecht R, Cornely OA, Flueckiger U, Frere P, Gachot B, Heinz WJ, Lass-Floerl C, Ribaud P, Thiebaut A, Bone Marrow Transplant 2011 46 5 709 718 10.1038/bmt.2010.175 20661235
67. Results of a randomized, double-blind trial of fluconazole (flu) vs. Voriconazole (vori) for the prevention of invasive fungal infections (ifi) in 600 allogeneic blood and marrow transplant (bmt) patients. Wingard JR, Carter SL, Walsh TJ, Kurtzberg J, Small TN, Gersten ID, Mendizabal AM, Leather H, Confer DL, Baden LR, Maziatz RT, Blood 2007 110 11
68. Voriconazole versus itraconazole for antifungal prophylaxis following allogeneic haematopoietic stem-cell transplantation. Marks DI, Pagliuca A, Kibbler CC, Glasmacher A, Heussel CP, Kantecki M, Miller PJ, Ribaud P, Schlamm HT, Solano C, Cook G, IMPROVIT Study Group, Br J Haematol 2011 155 3 318 327 10.1111/j.1365-2141.2011.08838.x 21880032
69. A double-blind trial on prophylactic voriconazole (vrc) or placebo during induction chemotherapy for acute myelogenous leukaemia (aml). Vehreschild JJ, Boehme A, Buchheidt D, Arenz D, Harnischmacher U, Heussel CP, Ullmann AJ, Mousset S, Hummel M, Frommolt P, Wassmer G, J Infect 2007 55 5
70. Posaconazole or fluconazole for prophylaxis in severe graft-versus-host disease-nejm. Ullmann A, Lipton J, Vesole DH, Chandrasekar P, Amelia L, Tarantolo S, Greinix H, Morais de Azevedo W, Reddy V, Boparai N, Pedicone L, N Engl J Med 2007 356 335 347 10.1056/NEJMoa061098 17251530 (Pubitemid 46148776)
71. Acyclovir prophylaxis of herpes-simplex-virus infections. Saral R, Burns WH, Laskin OL, Santos GW, Lietman PS, N Engl J Med 1981 305 2 63 67 10.1056/NEJM198107093050202 6264292
72. Acyclovir prophylaxis against herpes-simplex virus-infection in patients with leukemia-a randomized, double-blind, placebo-controlled study. Saral R, Ambinder RF, Burns WH, Angelopulos CM, Griffin DE, Burke PJ, Lietman PS, Ann Intern Med 1983 99 6 773 776 10.7326/0003-4819-99-6-773 6359995 (Pubitemid 14248403)
73. Long-term acyclovir for prevention of varicella zoster virus disease after allogeneic hematopoietic cell transplantation-a randomized double-blind placebo-controlled study. Boeckh M, Kim HW, Flowers MED, Meyers JD, Bowden RA, Blood 2006 107 5 1800 1805 10.1182/blood-2005-09-3624 16282339 (Pubitemid 43289356)
74. Cancer patients undergoing chemotherapy show adequate serological response to vaccinations against influenza virus and streptococcus pneumoniae. Nordoy T, Aaberge IS, Husebekk A, Samdal HH, Steinert S, Melby H, Kolstad A, Medical Oncology 2002 19 2 71 78 10.1385/MO:19:2:71 12180483 (Pubitemid 34625928)
75. Influenza in immunosuppressed populations: A review of infection frequency, morbidity, mortality, and vaccine responses. Kunisaki KM, Janoff EN, Lancet Infect Dis 2009 9 8 493 504 10.1016/S1473-3099(09)70175-6 19628174
76. Influenza immunization of adult patients with malignant diseases. Ortbals DW, Liebhaber H, Presant CA, Vanamburg AL, Lee JY, Ann Intern Med 1977 87 5 552 557 10.7326/0003-4819-87-5-552 921082 (Pubitemid 8223601)
77. Immunogenicity of vaccination against influenza, streptococcus pneumoniae and haemophilus influenzae type b in patients with multiple myeloma. Robertson JD, Nagesh K, Jowitt SN, Dougal M, Anderson H, Mutton K, Zambon M, Scarffe JH, Br J Cancer 2000 82 7 1261 1265 10.1054/bjoc.1999.1088 10755398 (Pubitemid 30145342)
78. Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: A retrospective case-control study. Vu D, Peck AJ, Nichols WG, Varley C, Englund JA, Corey L, Boeckh M, Clin Infect Dis 2007 45 2
79. Respiratory virus infections in adults with hematologic malignancies: A prospective study. Martino R, Ramila E, Rabella R, Munoz JM, Peyret M, Portos JM, Laborda R, Sierra J, Clin Infect Dis 2003 36 1 1 8 10.1086/344899 12491194 (Pubitemid 36099089)
80. Respiratory virus infection among hematopoietic cell transplant recipients: Evidence for asymptomatic parainfluenza virus infection. Peck AJ, Englund JA, Kuypers J, Guthrie KA, Corey L, Morrow R, Hackman RC, Cent A, Boeckh M, Blood 2007 110 5 1681 1688 10.1182/blood-2006-12-060343 17502457 (Pubitemid 47443987)
81. Parainfluenza virus infections after hematopoietic stem cell transplantation: Risk factors, response to antiviral therapy, and effect on transplant outcome. Nichols WG, Corey L, Gooley T, Davis C, Boeckh M, Blood 2001 98 3
82. Respiratory syncytial virus infection following hematopoietic stem cell transplantation. Small TN, Casson A, Malak SF, Boulad F, Kiehn TE, Stiles J, Ushay HM, Sepkowitz KA, Bone Marrow Transplant 2002 29 4 321 327 10.1038/sj.bmt.1703365 11896429 (Pubitemid 34229037)
83. Palivizumab treatment of respiratory syncytial virus infection after allogeneic hematopoietic stem cell transplantation. de Fontbrune FS, Robin M, Porcher R, Scieux C, de latour RP, Ferry C, Rocha V, Boudjedir K, Devergie A, Bergeron A, Gluckman E, Clin Infect Dis 2007 45 8 1019 1024 10.1086/521912 17879919 (Pubitemid 47580353)
84. Invasive adenoviral infections in t-cell-depleted allogeneic hematopoietic stem cell transplantation: High mortality in the era of cidofovir. Symeonidis N, Jakubowski A, Pierre-Louis S, Jaffe D, Pamer E, Sepkowitz K, O'Reilly RJ, Papanicolaou GA, Transpl Infect Dis 2007 9 2 108 113 10.1111/j.1399-3062.2006.00184.x 17461995 (Pubitemid 46669079)